Air Force Bases Renew Their Contracts With Cleantech Pioneer

1. BioLargo Inc. is a billboard sponsor of Streetwise Reports and pays SWR a monthly sponsorship fee between US$3,000 and US$6,000.
2. As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of BioLargo Inc.
3. Steve Sobek wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
4. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
5. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Disclosure for the quote from the John Newell article published on March 11, 2026

1. For the quoted article (published on March 11, 2026), BioLargo has paid Street Smart, an affiliate of Streetwise Reports, US$2,550.
2. Author Certification and Compensation: [John Newell of John Newell and Associates] was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Newell holds a Chartered Investment Management (CIM) designation (2015) and a  U.S. Portfolio Manager designation (2015). The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.

John Newell Disclaimer

As always it is important to note that investing in precious metals like silver carries risks, and market conditions can change violently with shock and awe tactics, that we have seen over the past 20 years. Before making any investment decisions, it's advisable consult with a financial advisor if needed. Also the practice of conducting thorough research and to consider your investment goals and risk tolerance.

2. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

Cleantech and life sciences innovator BioLargo Inc. (BLGO:OTCQX) announced today that its engineering division, BioLargo Engineering, Science & Technologies (BLEST), has secured contract renewals worth over US$1.4 million, according to a July 1 release.

These contracts, spanning 12 months, will allow BLEST to continue its air quality and environmental support services at five U.S. Air Force bases. As a subcontractor to the primary environmental contractors, BLEST's role encompasses a range of responsibilities including regulatory compliance, permitting, testing, air data management, compliance reporting, and inventory management. These renewals mark the continuation of multi-year efforts into their subsequent option year.

"These recurring Air Force contracts give BioLargo a base of repeatable engineering revenue, alongside larger engineering projects such as the pilot-scale mineral processing facility announced in April, as well as the company's ongoing product sales," BioLargo President and Chief Executive Officer Dennis P. Calvert said.

"Our teams have supported air quality and environmental compliance at these specific Air Force bases for years," BLEST President Randall Moore said. "Renewing this work means continuity for the installations and for the specialists who do it, and that continuity is what our prime-contractor partners rely on."

CEO Takes Equity Over Cash, Shares Locked to Performance Milestones

In a move that ties his compensation directly to BioLargo's long-term performance, Calvert received 699,569 shares of common stock on June 30, 2026, followed by an additional 219,914 shares on July 1, 2026, in exchange for a reduction in amounts owed to him by the company for salary and unreimbursed business expenses, according to a Form 4 filed with the SEC. 

The shares were valued at $0.1135 and $0.113 per share, respectively. Notably, the shares are subject to a lock-up agreement and cannot be sold until BioLargo reports at least US$40 million in consolidated gross revenue for any quarterly or annual period, its market capitalization exceeds US$300 million, or a change of control occurs.

BEST's Aquatech Partnership

In May, BioLargo announced that another subsidiary, BioLargo Equipment Solutions & Technologies Inc. (BEST), signed a memorandum of understanding (MOU) with Aquatech, a leader in water purification, to enhance global water safety. This partnership focuses on the integration and commercialization of BioLargo's Aqueous Electrostatic Concentrator (AEC) technology, which is designed to remove PFAS from water. This technology will be combined with Aquatech’s comprehensive PFAS treatment systems that include advanced destruction processes, aiming for full PFAS management with minimal waste.

The collaboration is set to strengthen both companies' offerings, enabling them to provide integrated solutions that adhere to the strict regulatory standards for PFAS treatment required in both the public and private sectors. Aquatech, recognized for its technical prowess and innovative approaches in water and wastewater management, was named Water Technology Company of the Year at the 2025 Global Water Awards in Paris. Their technology portfolio includes a range of advanced solutions such as membrane-based, thermal, biological, electrochemical, and ultrapure water treatment systems.

Tonya Chandler, president of BEST, expressed enthusiasm about the partnership at the time, stating, "By partnering with Aquatech — one of the most respected and capable organizations in the global water treatment industry — we can significantly amplify the reach and impact of our Aqueous Electrostatic Concentrator technology." She highlighted the combined expertise of both companies in engineering, science, and market experience, which will deliver scalable PFAS treatment solutions to industrial, municipal, and government clients.

The agreement establishes a non-exclusive collaboration framework, allowing both companies to utilize their complementary technologies to effectively meet the growing demands of the PFAS remediation market. Devesh Mittal, Vice President of Aquatech Environmental Services, commented on the synergy, saying, "Coupling BioLargo's AEC PFAS collection and concentration technology with Aquatech's PFAS removal and destruction expertise presents a powerful opportunity to fast-track effective solutions to serve the customer."

BioLargo emphasized that this MOU is part of its strategic approach to form strong alliances with industry leaders, which will help expand market reach and accelerate the adoption of its clean technologies.

Exclusive Clyra Distribution Agreement

Also in May, a third subsidiary, Clyra Medical Technologies Inc. announced an exclusive distribution agreement with Al-Hikma FZCO, a company based in Dubai, United Arab Emirates. Under this agreement, Al-Hikma FZCO will handle the commercialization of ViaCLYR™, an advanced wound irrigation solution developed by Clyra, across a broad region that includes the Gulf Cooperation Council, the Levant, North Africa, and several neighboring markets.

ViaCLYR™ utilizes Clyra's proprietary technology, Clyrasept™ Copper-Iodine Complex Solution (CICS), which is known for its broad-spectrum antimicrobial properties, biocompatibility, and support of natural healing processes.

The product has been recognized for its effectiveness in reducing wound fluid discharge, increasing healing activity early in treatment, and significantly reducing wound size and depth, particularly in pressure injuries.

ViaCLYR™ is described as a highly effective, tissue-safe, long-acting wound irrigation solution suitable for a wide range of acute and chronic wounds and burns. It is 510(k) cleared by the FDA and indicated for use in both acute and chronic wounds, boasting extremely high antimicrobial activity and sustained efficacy for up to 72 hours.

Expert: ViaCLYR™ Stands Out

¹Technical Analyst John Newell of John Newell & Associates shared his insights on the company in a review of the stock on March 11.

In his analysis for Streetwise Reports on March 11, Newell highlighted the advancements made by BioLargo, particularly with its Clyra technology, which is gaining recognition in the healthcare sector in the field of infection control and advanced wound care. 

BioLargo's approach involves advancing its proprietary technologies through rigorous scientific validation and partnering with established entities to broaden the reach of its innovations. The company's portfolio is diverse, encompassing solutions for advanced water treatment, environmental remediation, air quality control, long-duration energy storage, and medical technologies.

A standout within the portfolio, Clyra Medical Technologies, is noted for its copper-iodine antimicrobial solutions that are effective for up to 72 hours and are non-cytotoxic, making them suitable for wound management and surgical infections, Newell said. Clyra's leading product, ViaCLYR™, has received FDA 510(k) clearance, facilitating its distribution through established medical device channels. The technology is protected by approximately 40 issued and pending patents and is available in various formats including liquids, powders, hydrogels, and antimicrobial dressings.

In addition to its medical technologies, BioLargo is developing a long-duration energy storage system called the Cellinity™ battery. This innovation aims to overcome the limitations of traditional lithium-ion batteries for grid-scale applications by using earth-abundant materials to enhance longevity. The company plans to license this technology and collaborate with manufacturing facilities for its production.

Newell rated BioLargo as a Speculative Buy, pointing to multiple potential catalysts across its technology platforms. He commends the company's systematic approach to commercialization and partnership, which is well-aligned with the growing demands for advanced healthcare solutions and sustainable energy storage.

Oak Ridge Financial Analyst Richard Ryan provided an update on BioLargo on May 18, describing BioLargo's business model as a "hub and spoke format — invent/acquire a product, prototype/prove it out, partner with necessary third parties, and commercialize."

Ryan maintained his Buy rating on the stock.

He continued, "By commercializing technologies through operating subsidiaries, BLGO diversifies overall risk, maintains high levels of segment ownership while providing solutions to diversified, high-growth end markets."

PFAS, Wound Care Markets Continue to Grow

The global PFAS treatment market, valued at US$2.8 billion in 2025, is anticipated to expand significantly, growing to US$4.8 billion by 2033, according to Grand View Research.

This growth represents a compound annual growth rate (CAGR) of 7.1% from 2026 to 2033. In 2025, North America dominated the market, accounting for 41.9% of the global revenue, driven by stringent environmental regulations and high water quality standards.

"The PFAS treatment market is experiencing significant growth driven by increasing regulatory scrutiny of per- and polyfluoroalkyl substances (PFAS), growing concerns regarding water contamination, and rising investments in advanced water treatment infrastructure," Grand View said. "Governments and environmental agencies across North America, Europe, and Asia Pacific are implementing stricter drinking water standards and remediation requirements for PFAS compounds due to their persistence, bioaccumulation potential, and associated health risks."

Moreover, rapid urbanization and heightened concerns over water quality in regions like Asia Pacific, the Middle East, and Latin America are expected to offer significant long-term opportunities for technology providers and engineering service companies in the PFAS treatment sector.

Growing public awareness, ongoing assessments of contamination, and legal liabilities linked to PFAS pollution are prompting utilities, industries, and remediation services to invest in effective PFAS removal and destruction solutions, thereby supporting the sustained growth of the market, the report noted.

A recent study by Future Market Insights forecasts significant growth in the global market for anti-biofilm wound dressings, predicting a compound annual growth rate (CAGR) of 9.8% from 2025 to 2035. The market is expected to swell from US$943.5 million to US$2.4 billion over this decade, driven primarily by an increase in surgical site infections, diabetic ulcers, and chronic wounds. Biofilms, which complicate healing processes and contribute to antibiotic resistance, are a major factor spurring the need for these advanced wound care solutions.

In the United States, the market for anti-biofilm wound dressings is projected to grow at a CAGR of 9.3%. This growth is supported by several factors including an aging population, a rise in the prevalence of chronic wounds, advancements in medical technology, and government initiatives aimed at enhancing healthcare outcomes. These elements collectively underscore a growing demand for effective wound care products that can manage complex wound environments and resist biofilm formation, thereby improving healing rates and reducing the burden of wound care on healthcare systems.

Ownership and Share Structure²

About 13.62% of BioLargo is owned by insiders and management. About 0.04% is held by institutions with13F-disclosed institutional holdings only. The rest, 86.34%, is retail.

Its market cap is US$35.62 million, with about 320.88 million shares outstanding and about 276.31 million free-floating. It trades in a 52-week range of US$0.10 and US$0.23.